

RECEIVED  
CENTRAL FAX CENTER

APR 18 2008

REMARKS

In response to the restriction requirement, Applicants elect the Group II invention, claims 5-17, with the right to file one or more divisional applications on the non-elected claims. Accordingly, claims 5-17 are before the Examiner for consideration on their merits and claims 1-4 and 18-21 are withdrawn from consideration.


This filing also responds to the objection to the application with respect to the failure to meet certain sequencing rules and specifically that the sequence listings found in the claims and specification do not contain sequence identifiers. This problem is overcome by the identification of the sequence identifiers for claim 11, which is the only claim before the Examiner for consideration. Since claims 2 and 22 are withdrawn from consideration, they are not revised.

The recitations of the sequences in the specification are also revised to reference the sequence identifier.

It is submitted that this is a complete response to the issues raised in the outstanding Office Action so that an examination on the merits of this application can be received.

Applicants respectfully submit that there is no fee required for this submission, however, please charge any fee deficiency or credit any overpayment to Deposit Account No. 50-1088.

Respectfully submitted,  
CLARK & BRODY

  
Christopher W. Brody  
Registration No. 33,613

Customer No. 22902  
1090 Vermont Avenue, NW, Suite 250  
Washington, DC 20005  
Telephone: 202-835-1111  
Facsimile: 202-835-1755  
Docket No.: 12007-0047  
Date: April 18, 2008